David Mittelman
About David Mittelman
David Mittelman is the Founder and Chief Executive Officer of Othram Inc, a company that specializes in advanced DNA sequencing and genomics for forensic applications. He has held various significant positions in academia and industry, advocating for the use of DNA technology to address complex cases in the justice system.
Work at Othram
David Mittelman serves as the Founder and Chief Executive Officer of Othram Inc, a position he has held since 2018. Under his leadership, Othram has established itself as the only laboratory in the United States that provides fully in-house DNA evidence testing services. Mittelman promotes the application of advanced DNA sequencing and genomics to address cases that traditional forensic methods cannot resolve. He advocates for the scaling of DNA technology to assist victims, their families, and individuals wrongfully accused.
Education and Expertise
David Mittelman earned a PhD in Molecular Biophysics from Baylor College of Medicine, where he studied from 2002 to 2007. Prior to that, he completed a Bachelor of Science in Neuroscience at The University of Texas at Dallas from 1998 to 2001. His educational background laid the foundation for his extensive career in genetics and molecular biology, contributing to his expertise in DNA technology and forensic applications.
Background
David Mittelman's professional journey includes significant roles in various organizations. He worked as a Postdoctoral Fellow at Baylor College of Medicine from 2007 to 2009 and later held positions as an Associate Professor at Virginia Tech from 2010 to 2013. He co-founded Arpeggi Inc and served as its Chief Scientific Officer for nine months in 2012 to 2013. His experience also includes roles at Elite Surgical Affiliates and Gene by Gene, where he held leadership positions in scientific and operational capacities.
Achievements
Throughout his career, David Mittelman has contributed to the advancement of DNA technology in forensic science. He has been involved in initiatives that encourage public participation in solving cases through dnasolves.com, a platform that features cases needing resolution and updates on progress. His work has focused on leveraging genomic advancements to benefit victims and address unsolved cases, showcasing his commitment to the field.